Author argues Novocure's FDA approval for Optune Pax in pancreatic cancer is underappreciated and the $1.5B market cap is too low.
NVCR — LONG The author argues Novocure's faster-than-expected FDA approval of Optune Pax for locally advanced pancreatic cancer demonstrates real clinical need, and that even after the rally the ~$1.5B market cap is far too low. The catalyst is the FDA approval itself, which the author frames as validating the wearable device's value in extending life by two months. The author implies upside remains despite the premarket gain of up to 34%.
Faster than expected FDA approval for NVCR shows the need. Even with the rally, $1.5bb cap is far too low. Two months additional life is meaningful.
This Reddit post, published February 12, 2026, features u/Always_Curious_One2 discussing NVCR. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Always_Curious_One2 · Tickers: NVCR